Mon premier blog

Polymorphism in the pharmaceutical industry by Rolf Hilfiker

Polymorphism in the pharmaceutical industry Rolf Hilfiker ebook
Publisher: Wiley-VCH
Page: 433
ISBN: 3527311467, 9783527311460
Format: pdf

The need to find rare Life Science Research; Pharmaceuticals/ Pharmacogenomics; Agriculture/ Breeding; Diagnostics. Validates and extends previous findings. In his painstakingly 275-page decision, the single judge, Justice Manmohan Singh opined that the generic product Erlocip manufactured and sold by Cipla contains polymorphic B variant of Erlotinib hydrochloride as active ingredient and hence do not infringed the compound per se claims of the It is likely that the reasoning of this decision may add yet another disappointment and further dismay for the pharmaceutical companies in enforcing their patents in India . Pharmacogenomics in clinical trials is a relatively new area in which considerable hesitation is shown by pharmaceutical companies. Processing-induced Phase Transformations and Their Implications on Pharmaceutical Product Quality. 2009;11(4):740-6; Govindarajan R, Suryanarayanan R. Due to this reason, Despite recent technological challenges faced by this industry, there is still strong growth potential and money in this market. SNP (single nucleotide polymorphism) analysis is the most common type of genetic variation between human beings and can be ideal for identifying the correlation between genotype and behavior of living organisms. Variations in drug response due to polymorphism of receptors can be illustrated with β2 adrenergic receptor polymorphisms, where homozygous mutants with decreased expression of β2 adrenergic receptors do not have a predictable response to the use of drugs like salbutamol in asthma. Similarly, polymorphisms of transporters . What is perhaps more exciting, he says, is that “incrementally, this strengthens the evidence that a relatively uncommon polymorphism that lowers LDL substantially through PSCK9 mechanisms translates into differences in IHD.” The pharmaceutical industry is currently looking at PSCK9 inhibition as a target for cardiovascular disease, “and these data certainly support that effort,” he maintains.